Endovascular

Exemplary Cases From the LIFE-BTK Trial

20 min.

Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

21 min.

Angiographic and Clinical Outcomes of the Thin-Strut MAGNITUDE Bioresorbable Scaffold in Patients with Below-the-Knee Arterial Disease: Early Results from the RESOLV I Trial

9 min.

New BTK Bioresorbable Stent Technology: Life BTK, The MOTIV-BTK Trial and R3 Clinical Programs

10 min.

Yes: There Is Always Room For Better Stents

24 min.

No: Current DES Are Better Than Ever

6 min.

R3 Vascular MAGNITUDE Bioresorbable Drug Eluting Scaffold

6 min.

Bioresorbable Stent Technology for BTK Disease: Putting the Trials Into Perspective

7 min.

Iliocaval Stenting and Reconstructions With Extreme Case Examples

12 min.

New technology update for CLI : Scaffolds

8 min.

Scaffolds Are Back: What's Old Is New

7 min.

Role of Drug-Eluting Technologies as Definitive Therapy

8 min.

Reflow Medical’s Temporary Spur DES System

3 min.

MOTIV BRS (REVA Vascular)

4 min.

APTITUDE PLLA BRS (R3 Vascular)

4 min.

Hybrid Nano-Coating DES for BTK Disease

6 min.

First Safety and Efficacy Study of the Misago Stent in Lower Extremity Endovascular Interventions via Radial Access Approach

8 min.

Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial

7 min.

Endovascular Sequestration of High-Risk Carotid Lesions Using the MicroNET-Covered Embolic Prevention Stent in Consecutive Patients With Symptoms or Signs of Carotid Stenosis-Related Cerebral Injury: An Investigator-Initiated, Intravascular, Ultrasound-Controlled, Multinational, Multispecialty Trial (CGuard OPTIMA)

5 min.

Have We Gotten to the Final Word on Paclitaxel Safety?

9 min.